Literature DB >> 16935207

Molecular biology of choroidal neovascularization.

Ming Lu1, Anthony P Adamis.   

Abstract

VEGF plays a pivotal role in the neovascularization of the choroid in AMD. Anti-VEGF agents have been developed to target VEGF itself or its receptor signal transduction pathway, and have shown promising results in clinical trials. The combination of anti-VEGF strategies with established treatment modalities may have additional efficacy. Safe and effective drug-delivery systems are also required for the successful anti-VEGF therapies for AMD and other ocular diseases with CNV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935207     DOI: 10.1016/j.ohc.2006.05.001

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  28 in total

Review 1.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

2.  Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.

Authors:  Venugopal Gunda; Yakkanti A Sudhakar
Journal:  J Cancer Sci Ther       Date:  2013-07-04

3.  Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid.

Authors:  Kavita V Bhavsar; K Bailey Freund
Journal:  Saudi J Ophthalmol       Date:  2014-03-12

4.  Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.

Authors:  Ji Jin; Kevin K Zhou; Kyoungmin Park; Yang Hu; Xun Xu; Zhi Zheng; Puneet Tyagi; Uday B Kompella; Jian-xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-05       Impact factor: 4.799

5.  Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.

Authors:  Yanxiong Mao; Szilard Kiss; Julie L Boyer; Neil R Hackett; Jianping Qiu; Andrew Carbone; Jason G Mezey; Stephen M Kaminsky; Donald J D'Amico; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2011-10-27       Impact factor: 5.695

Review 6.  Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.

Authors:  Nupura S Bhise; Ron B Shmueli; Joel C Sunshine; Stephany Y Tzeng; Jordan J Green
Journal:  Expert Opin Drug Deliv       Date:  2011-02-22       Impact factor: 6.648

Review 7.  Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.

Authors:  Claudio Campa; Ciro Costagliola; Carlo Incorvaia; Carl Sheridan; Francesco Semeraro; Katia De Nadai; Adolfo Sebastiani; Francesco Parmeggiani
Journal:  Mediators Inflamm       Date:  2010-08-25       Impact factor: 4.711

8.  Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Authors:  Henry F Edelhauser; Jeffrey H Boatright; John M Nickerson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

9.  Pathogenic role of the Wnt signaling pathway activation in laser-induced choroidal neovascularization.

Authors:  Yang Hu; Ying Chen; Mingkai Lin; Kyungwon Lee; Robert A Mott; Jian-xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

10.  The effects of anti-VEGF and kinin B1 receptor blockade on retinal inflammation in laser-induced choroidal neovascularization.

Authors:  Soumaya Hachana; Olivier Fontaine; Przemyslaw Sapieha; Mark Lesk; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.